Caribou Biosciences

Q2 FY2026 EarningsQ2 FY26 results beat consensus on bottom-line metrics despite a miss on revenue. GAAP net loss was -$24.3M (-$0.24 EPS) compared to the expected -$31.1M (-$0.32 EPS), driven by aggressive cost-cutting measures including a 31.6% YoY reduction in R&D expenses. While licensing revenue of $1.5M fell short of the $2.2M forecast, clinical data for vispa-cel and CB-011 remains competitive with autologous therapies. Cash runway is now extended through 2027, though funding for the pivotal Phase 3 ANTLER-3 trial remains a key strategic hurdle.